Drug Profile
Research programme: anti-cancer therapeutics - Sapience Therapeutics/University of Bath
Alternative Names: cFos mimetic; ST201Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Sapience Therapeutics; University of Bath
- Class Antineoplastics; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 May 2022 No recent reports of development identified for research development in Cancer in USA
- 05 Apr 2018 Sapience Therapeutics and University of Bath agree to co-promote and co-develop anti-cancer therapies for Cancer